CTOs on the Move

C3 Jian Inc

www.c3-jian.com

 
C3 Jian Inc is a Inglewood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $250-500 Million
  • www.c3-jian.com
  • 423 Hindry Ave Ste D
    Inglewood, CA USA 90301
  • Phone: 310.665.2928

Executives

Name Title Contact Details

Similar Companies

Vivace Therapeutics

Vivace Therapeutics is a venture-backed, oncology-focused portfolio-based drug discovery and development company, based in San Mateo, California. Its programs include both small molecule programs targeting the YAP pathway, and bi-specific programs.

Center for Breakthrough Medicines

The Center for Breakthrough Medicines is the Worlds Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.

www.mycomedica.bio

Co-Founded by world-renowned mycologist Paul Stamets, MycoMedica, PBC is a life sciences company developing therapeutic drugs derived from fungi to help people live healthier, better lives.

Ariana Pharma

Ariana is a spin-off of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis.

Myovant

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.